Strategic Pivot: 180 Life Sciences Rebrands as ETHZilla with Major Treasury Shift

In a dramatic strategic overhaul, 180 Life Sciences Corp. is rebranding as ETHZilla and shifting its core focus to digital asset treasury management. The company announced significant updates concerning its substantial Ethereum holdings, a major financing arrangement, and changes to its executive leadership, moves that are fundamentally reshaping its investment narrative.

Leadership Restructuring and Corporate Rebranding

This strategic redirection coincides with a change at the helm. Effective September 4, McAndrew Rudisill, the company’s former Chairman, assumed the role of Chief Executive Officer. He succeeded Blair Jordan, who stepped down from the position on that same date. The corporate rebranding to ETHZilla underscores this new chapter dedicated to cryptocurrency strategy.

Substantial Digital and Liquid Reserves

Central to this new direction is the company’s formidable treasury. ETHZilla currently holds a crypto portfolio of 102,246 Ether. At current market valuations, this Ethereum cache is worth approximately $443 million. Beyond its digital assets, the firm maintains a robust war chest of around $213 million in cash and other liquid instruments, providing significant financial flexibility.

Key Treasury Figures:
* Ether Holdings: 102,246 ETH
* Portfolio Valuation: ~$443 million
* Cash Reserves: ~$213 million

Should investors sell immediately? Or is it worth buying 180 Life Sciences?

Financing Share Repurchases with Crypto Collateral

To fund its ambitious capital return program, the company has engaged in an over-the-counter (OTC) financing transaction with Cumberland DRW. This agreement provides access to up to $80 million, which is secured against a portion of the company’s ETH holdings. The capital from this deal is earmarked for an already-announced $250 million share repurchase initiative.

The buyback program is already underway. Management has repurchased approximately 2.2 million shares at an average price of $2.50, reducing the total number of outstanding shares by 1.3%. The leadership team characterizes these buybacks as an opportunistic and value-accretive use of capital, especially given that the stock has been trading significantly below its net asset value (NAV).

Market Volatility Reflects Investor Uncertainty

The decisive pivot into financing crypto-backed strategies has polarized investor opinion, resulting in notable stock price volatility. The equity experienced sharp swings, including a 17% decline early in the month. This followed a 4.5% gain in mid-August, which coincided with the announcement of a separate plan for a potential stock issuance of up to $500 million. These pronounced price movements highlight the perceived risks and uncertainties associated with the company’s new strategic path.

Market participants are now closely monitoring how this substantial capital infusion, combined with fresh executive leadership, will ultimately reshape the company’s unique investment proposition at the intersection of biotechnology and digital assets.